Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, and American Molecular Imaging (AMI), one of the leading radiology reading services providers in the U.S., are pleased to announce that they have entered into a strategic business and investment agreement (the “Agreement”), with the goal of ensuring that all patients of Algernon’s planned U.S. brain-specific neuroimaging clinics receive the highest quality Positron Emission Tomography (PET) scan radiology exam interpretations and reports available, within an industry leading timeframe.

Algernon’s planned neuroimaging clinics will be the first dedicated, brain optimized PET neuroimaging facilities of their kind in the U.S., focussed on the early-stage detection of Alzheimer’s Disease, and will also provide PET scans for other forms of dementia, epilepsy, neuro-oncology, and movement disorders.

As part of the Agreement, AMI will be awarded the exclusive radiology reading services contract for all of Algernon’s planned U.S. neuroimaging clinics. AMI will also be making an aggregate, USD $250,000 strategic investment in both Algernon’s recently announced private placement and USD $250,000 in Algernon USA LLC, a recently created subsidiary of Algernon, that will oversee all U.S. neuroimaging operations, including the opening of the first U.S.-based neuroimaging clinic, being planned for early 2026. The agreement with Algernon USA LLC is subject to definitive documentation which is expected to be signed within the next 60 days.

“We are very pleased to have entered into this Agreement with AMI,” said Christopher J. Moreau, CEO of Algernon Health. “Since announcing our new Alzheimer’s Disease initiative, we have been carefully and methodically establishing relationships with the leading companies and experts in nuclear imaging in the U.S. By bringing together and working with the best of the best, we can ensure that we deliver the highest level of patient care possible while operating our clinics effectively and efficiently.”

Jaideep Sohi, M.D., CEO of American Molecular Imaging stated, “Since founding AMI, I have always strived to build a world class company that would be recognized as a global leader in the field of nuclear medicine. We are truly excited to be a part of Algernon’s plan to bring this new brain optimized PET scan technology to the market and to join forces in making a serious contribution in the fight against Alzheimer’s Disease.”

American Molecular Imaging is a physician-owned and managed company that specializes in teleradiology and theranostics services. It provides specialized professional radiology interpretation, focusing on molecular imaging, nuclear medicine, and diagnostic imaging exams to support healthcare providers nationwide.

Algernon also recently announced that it had signed a definitive equipment order, financing agreement, and consulting arrangement with industry-leading Catalyst MedTech for the provision of four, U.S. FDA-cleared Oncovision CareMiBrain™ brain-specific, Positron Emission Tomography (PET) scanner systems to be utilized in four planned Algernon neuroimaging medical clinics. This represents a non-dilutive deal valued at over CAD $4 million and includes an agreement to acquire an additional six systems for the establishment of additional U.S. clinics, on an adjusted cost basis.

Algernon will further update the market shortly on its upcoming expansion and growth plans, including the location of it first U.S. flagship neuroimaging clinic.

Any Algernon Health Inc. securities issued and issuable, described in this news release, will be subject to a statutory hold period of four months plus a day from the date of issuance in   accordance with applicable Canadian securities legislation.

The Algernon Health Inc. securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration.

Christopher J. Moreau
CEO
Algernon Health Inc.
604.398.4175 Ext 701
cjmoreau@algernonhealth.com

https://www.algernonhealth.com/

About American Molecular Imaging

American Molecular Imaging (AMI) is a physician-owned and managed company based in the United States that specializes in teleradiology and theranostics services. It provides specialized professional radiology interpretation, focusing on molecular imaging, nuclear medicine, and diagnostic imaging exams to support healthcare providers nationwide. AMI aims to deliver accurate, timely interpretations using state-of-the-art technology, with an emphasis on subspecialty expertise, fast turnaround times, and patient-centric care, particularly in underserved areas. The company helps facilities optimize advanced imaging services like PET/CT and nuclear cardiology, and it participates in clinical trials to advance the field.

About Dr. Jaideep Sohi – CEO AMI

Dr. Jaideep S. Sohi, M.D. is a nationally recognized leader in nuclear medicine and molecular imaging, bringing exceptional expertise in both diagnostic and therapeutic applications. He completed his residency at the University of Iowa, one of the nation’s top programs, where he also served as Chief Resident. He went on to pursue a highly competitive fellowship in PET/CT Imaging at Johns Hopkins University, further refining his subspecialty expertise.

With a distinguished career spanning clinical practice, research, and education, Dr. Sohi has established himself as a trusted authority in PET/CT and advanced molecular imaging. He currently serves as clinical faculty at Northwestern University, where he is dedicated to mentoring the next generation of physicians. He is equally passionate about sharing knowledge with peers, leading comprehensive outreach programs to educate clinicians on emerging imaging tracers and their applications in patient care.

About Algernon Health  

Algernon Health is a Canadian healthcare company focused on the provision of brain optimized PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s Disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a recently created private subsidiary called Algernon USA LLC, that will oversee all U.S. neuroimaging operations.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to planned brain-specific neuroimaging PET scanning clinic opening timelines, planned financings in the Company and its subsidiary and the closings thereof, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.